Inhibitory effects of sesamin on CYP2C9-dependent 7-hydroxylation of S-warfarin
A recent report demonstrated that sesamin strongly and non-competitively inhibits S-warfarin 7-hydroxylation activity in human liver microsomes with a Ki value of 0.2 μM. This finding suggests that sesamin predominantly binds to CYP2C9 at another site for which it has a higher affinity than its affi...
Saved in:
Published in | Drug metabolism and pharmacokinetics Vol. 35; no. 4; pp. 368 - 373 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.08.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A recent report demonstrated that sesamin strongly and non-competitively inhibits S-warfarin 7-hydroxylation activity in human liver microsomes with a Ki value of 0.2 μM. This finding suggests that sesamin predominantly binds to CYP2C9 at another site for which it has a higher affinity than its affinity for the active site, thereby inhibiting the activity of CYP2C9 non-competitively. In this study, we found that sesamin competitively inhibited the 7-hydroxylation activity of S-warfarin in human liver microsomes with a Ki value of 15.7 μM. In addition, the recombinant CYP2C9-dependent 7-hydroxylation activity of S-warfarin was competitively inhibited by sesamin with a Ki value of 13.1 μM. These results are consistent with the fact that sesamin is a good substrate of CYP2C9, and its activity follows Michaelis-Menten kinetics. As the plasma concentration of sesamin after its administration is usually lower than 0.01 μM, the inhibition of S-warfarin metabolism by sesamin does not appear to be severe.
CYP2C9-dependent competitive reactions and inhibitions between S-warfarin and sesamin. [Display omitted] |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1347-4367 1880-0920 |
DOI: | 10.1016/j.dmpk.2020.05.002 |